Kim E Kortekaas
Overview
Explore the profile of Kim E Kortekaas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Velzen A, Tulling A, van Poelgeest M, Bosse T, van Doorn H, Kortekaas K, et al.
Gynecol Oncol
. 2025 Feb;
194:86-90.
PMID: 39983351
Objective: This study aimed to analyze the risk of lymph node metastases (LNM) in three different VSCC subgroups (HPV-positive (HPVpos), HPV-negative p53 wildtype (HPVneg/p53wt) and HPV-negative p53 abnormal (HPVneg/p53abn)), and...
2.
Abdulrahman Z, Kortekaas K, Welters M, van Poelgeest M, van der Burg S
Cancer Immunol Immunother
. 2024 Jul;
73(9):166.
PMID: 38954042
Background: Vulvar squamous cell carcinoma (VSCC) arises after an HPV infection or the mutation of p53 or other driver genes and is treated by mutilating surgery and/or (chemo) radiation, with...
3.
van Poelgeest M, Kortekaas K, van Doorn H, Oonk M, Nijman H, Boere I, et al.
Int J Gynecol Cancer
. 2024 Jun;
PMID: 38909994
Background: Vulvar squamous cell carcinoma (VSCC) is a rare cancer for which the cornerstone of treatment is surgery with high complication rates. The unmet need is a less radical and...
4.
Kortekaas K, Santegoets S, Tas L, Ehsan I, Charoentong P, van Doorn H, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34716208
Background: A profound insight into the immune landscape of vulvar squamous cell carcinoma (VSCC) is lacking. Here, an in-depth interrogation of T cell infiltration, local immune contexture, signaling pathways and...
5.
Kortekaas K, Bastiaannet E, van Doorn H, de Vos van Steenwijk P, Ewing-Graham P, Creutzberg C, et al.
Gynecol Oncol
. 2020 Sep;
159(3):649-656.
PMID: 32972785
Objective: There is great need for better risk stratification in vulvar squamous cell carcinoma (VSCC). Our aim was to define the prognostic significance of stratifying VSCC based on p16 and...
6.
Kortekaas K, Santegoets S, Sturm G, Ehsan I, van Egmond S, Finotello F, et al.
Cancer Immunol Res
. 2020 Aug;
8(10):1311-1321.
PMID: 32759363
The accumulation of tumor-specific CD4 and CD8 effector T cells is key to an effective antitumor response. Locally, CD4 T cells promote the recruitment and effector function of tumor-specific CD8...
7.
Kortekaas K, Solleveld-Westerink N, Tessier-Cloutier B, Rutten T, Poelgeest M, Gilks C, et al.
Histopathology
. 2020 Apr;
77(1):92-99.
PMID: 32236967
Aims: The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its prognostic value, particularly in HPV-independent VSCC, is uncertain. In other tumours, p53 immunohistochemistry (IHC)...
8.
Tessier-Cloutier B, Kortekaas K, Thompson E, Pors J, Chen J, Ho J, et al.
Mod Pathol
. 2020 Mar;
33(8):1595-1605.
PMID: 32203095
The recent literature has shown that vulvar squamous cell carcinoma (VSCC) can be stratified into two prognostically relevant groups based on human papillomavirus (HPV) status. The prognostic value of p53...
9.
Kortekaas K, Santegoets S, Abdulrahman Z, van Ham V, van der Tol M, Ehsan I, et al.
J Immunother Cancer
. 2019 Sep;
7(1):236.
PMID: 31481117
Background: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune...
10.
Kortekaas K, Van de Vijver K, van Poelgeest M, Gilks C, Smit V, Arif S, et al.
Int J Gynecol Pathol
. 2019 Aug;
39(5):420-427.
PMID: 31460873
Surgical resection with free surgical margins is the cornerstone of successful primary treatment of vulvar squamous cell carcinoma (VSCC). In general reexcision is recommended when the minimum peripheral surgical margin...